Q3 Earnings Forecast for ELVN Issued By HC Wainwright

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Research analysts at HC Wainwright issued their Q3 2026 earnings estimates for Enliven Therapeutics in a research note issued to investors on Monday, October 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($0.41) for the quarter. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.74) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.52) EPS and Q4 2027 earnings at ($0.55) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10).

A number of other analysts have also weighed in on ELVN. Zacks Research lowered shares of Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Morgan Stanley started coverage on Enliven Therapeutics in a research report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 target price for the company. The Goldman Sachs Group boosted their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. JonesTrading increased their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Stifel Nicolaus raised their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $75.44.

Enliven Therapeutics Trading Up 6.6%

NASDAQ:ELVN opened at $41.25 on Wednesday. The business’s fifty day moving average is $51.25 and its 200 day moving average is $47.98. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Enliven Therapeutics in the 2nd quarter worth approximately $221,255,000. First Light Asset Management LLC boosted its holdings in Enliven Therapeutics by 574.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after buying an additional 1,158,883 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Enliven Therapeutics by 276.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock worth $52,898,000 after acquiring an additional 847,399 shares during the period. Rock Springs Capital Management LP grew its holdings in Enliven Therapeutics by 3.5% during the 1st quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock valued at $32,399,000 after buying an additional 28,095 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in Enliven Therapeutics during the second quarter valued at $30,617,000. Institutional investors own 95.08% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mika K. Derynck sold 158,795 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the transaction, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the sale, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,913,300. This represents a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 183,831 shares of company stock valued at $10,823,298. 3.00% of the stock is currently owned by corporate insiders.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.